Department of Anesthesiology, Ditmanson Medical Foundation Chia‑Yi Christian Hospital, Chiayi 60002, Taiwan, R.O.C.
Cancer Research Center, Changhua Christian Hospital, Changhua 500209, Taiwan, R.O.C.
Mol Med Rep. 2022 Jan;25(1). doi: 10.3892/mmr.2021.12552. Epub 2021 Dec 3.
Among the different types of oral cancer, >90% of cases are oral squamous cell carcinoma (OSCC). 5‑fluorouracil (5‑FU) is a commonly used treatment for OSCC, but cells typically display resistance to the drug. Propofol, an intravenous anesthetic agent, exhibits certain anticancer effects, including the inhibition of cancer cell proliferation, migration and invasion. Secreted proteins, such as growth factors and cytokines are involved in cancer development and progression, but the effect of propofol on secreted proteins in OSCC is not completely understood. An MTT assay, flow cytometry and western blotting were performed to determine the anticancer effects of propofol. The secretion profile of OSCC was determined using an antibody array, and clinical importance was assessed using the Gene Expression Profiling Interactive Analysis database. The results were verified by performing reverse transcription‑quantitative PCR (RT‑qPCR) and western blotting. 5‑FU‑resistant cells were established to determine the role of the gene of interest in drug resistance. The results demonstrated that propofol decreased cell viability and promoted cell apoptosis. The antibody array results showed that propofol attenuated the secretion of multiple growth factors. The bioinformatics results indicated that amphiregulin (AREG) was expressed at significantly higher levels in cancer tissues, which was also related to poor prognosis. The results of RT‑qPCR and western blotting revealed that propofol decreased AREG expression. Pretreatment with exogenous recombinant AREG increased EGFR activation and conferred propofol resistance. Moreover, the results indicated that the expression and activation of AREG was also related to 5‑FU resistance, but propofol ameliorated 5‑FU drug resistance. Therefore, the present study suggested that propofol combination therapy may serve as an effective treatment strategy for OSCC.
在不同类型的口腔癌中,>90%的病例为口腔鳞状细胞癌(OSCC)。5-氟尿嘧啶(5-FU)是 OSCC 的常用治疗药物,但细胞通常对该药物产生耐药性。异丙酚是一种静脉麻醉剂,具有一定的抗癌作用,包括抑制癌细胞增殖、迁移和侵袭。分泌蛋白,如生长因子和细胞因子,参与癌症的发生和发展,但异丙酚对 OSCC 分泌蛋白的影响尚不完全清楚。采用 MTT 法、流式细胞术和 Western blot 法检测异丙酚的抗癌作用。采用抗体阵列检测 OSCC 的分泌谱,采用基因表达谱分析交互分析数据库评估临床重要性。通过反转录-定量 PCR(RT-qPCR)和 Western blot 验证结果。建立 5-FU 耐药细胞,以确定目的基因在耐药中的作用。结果表明,异丙酚降低细胞活力并促进细胞凋亡。抗体阵列结果表明,异丙酚减弱了多种生长因子的分泌。生物信息学结果表明,在癌组织中, Amphiregulin(AREG)的表达水平显著升高,这也与预后不良有关。RT-qPCR 和 Western blot 结果显示,异丙酚降低 AREG 表达。外源性重组 AREG 预处理增加 EGFR 激活并赋予异丙酚耐药性。此外,结果表明 AREG 的表达和激活也与 5-FU 耐药性有关,但异丙酚改善了 5-FU 耐药性。因此,本研究表明,异丙酚联合治疗可能是治疗 OSCC 的有效策略。